Objective: To understand the relationship between C-erbB-2 and multidrug resistance (MDR) as well as its clini- cal significance. Methods: P-gp level was detected by flow cytometry and simultaneously to examine the C-...Objective: To understand the relationship between C-erbB-2 and multidrug resistance (MDR) as well as its clini- cal significance. Methods: P-gp level was detected by flow cytometry and simultaneously to examine the C-erbB-2 expression level by immunohistochemistry assay in the operating samples. Their relationship was analyzed from 59 cases with gastric carcinoma. Results: The P-gp positive expression was 38/59 (64.4%) cases with gastric carcinoma. The C-erbB-2 positive expression was 21/59 (35.6%) cases with gastric carcinoma. From the analysis of the P-gp and C-erbB-2 relationship, which was involving, range in the gastric carcinoma, that involving two or three sites were more than the site one, in the cases with C-erbB-2 negative. Compared this two groups, there was a significant difference (P = 0.026). When the C-erbB-2 was positive, the P-gp expression had a significant difference (P = 0.04) in comparing the III–IV stage (lymph node metastasis) with I–II stage (without lymph node metastasis). The tumor’s size, differentiation degree, ages and sex were not related to the C-erbB- 2 and P-gp expression. Conclusion: High level of P-gp expression was related to the C-erbB-2 positive expression in clinical III–IV stage patient with gastric carcinoma (lymph node metastasis). It suggested that the double positive patient might be a poor prognosis. However, when the C-erbB-2 was negative expression, the clinical staging (with lymph node metastasis) was not related to the P-gp expression in gastric carcinoma patients.展开更多
Objective: To evaluate factors for prognosis of cervical carcinoma. Methods: Expressions of mn23- HI, erbB3 and erbB4 were examined by immunohistochemical staining. The apoptosis was detected in situ by the TdT mediat...Objective: To evaluate factors for prognosis of cervical carcinoma. Methods: Expressions of mn23- HI, erbB3 and erbB4 were examined by immunohistochemical staining. The apoptosis was detected in situ by the TdT mediated duip-biotin nick end-labeling (TUNEL) technique. Mitotic cell were counted by HE dyeing. Results: FIGO stage and lymph node metastasis were the most important factors for evaluating prognosis in adenocarcinoma or squamous cell carcinoma. AI/MI was positively correlated with 5-year survival of cervical carcinoma. Positive expression of nm23-H1 combed with negative expression of erbB4 [nm23-H1(+)/erbB4(?)] predicted good prognosis for adenocarcinoma. In multivariable Cox regression analysis, only FIGO stage and AI/MI were into equation. Conclusion: FIGO stage and AI/MI were independent evaluating parameter for adenocarcinoma or squamous cell carcinoma.展开更多
Objective: Aberrant expression of c-erbB-2, p53, p16 has been found in oral squamous cell carcinoma. We therefore examined expression of these proteins in squamous cell carcinoma of the anterior tongue and compared th...Objective: Aberrant expression of c-erbB-2, p53, p16 has been found in oral squamous cell carcinoma. We therefore examined expression of these proteins in squamous cell carcinoma of the anterior tongue and compared their relationship with clinical stages and prognosis. Methods: Seventy-six patients with squamous cell carcinoma of the anterior tongue never treated before were obtained from Cancer Hospital, CAMS. Archive tissues of carcinoma and paracarcinoma were examined for c-erbB-2, p53 and p16 expression by immunohistochemistry. Results: The rates of immunopositive staining of c-erbB-2, p53 and p16 were 64.5%, 61.8% and 23.7% respectively; the positive rates in paracarcinoma mucosa were 19.7%, 22.6% and 55.3% respectively. Overexpression of c-erbB-2 was significantly correlated with short overall survival, metastasis and staging. Overexpression of paracarcinoma p53 was significantly correlated with local recurrence. Conclusion. c-erbB-2 may be used as a prognosis marker for the patients with squamous cell carcinoma of the anterior tongue and p53 as a recurrence marker.展开更多
To assess the relationship between C-erbB-2, p53, N-ras status at a premalignant stage and in HCC, the authors studied the imunohistological expression of these genes in HCC, liver cirrhosis and in the adjacent normal...To assess the relationship between C-erbB-2, p53, N-ras status at a premalignant stage and in HCC, the authors studied the imunohistological expression of these genes in HCC, liver cirrhosis and in the adjacent normal resected liver tissue, using monoclonal antibody to mutated p53 and activated C-erbB-2, N-ras. C-erbB-2 was expressed in 97.1% (35/36) of HCC and 100% (18/18) of hepatic cirrhosis, low level C-erbB-2 expression was observed in 2/14 (14.3%) of normal liver specimens; The positive incidence of overexpression of mutant p53 protein in HCC and hepatic cirrhosis were 55.6% (20/36) and 66.7% (10/18) respectively; 29 (76.5%) specimens of HCC and 16 (88.9%) of hepatic cirrhosis were positive for N-ras protein. The overexpression of the three oncogene proteins were significantly higher than that of normal liver tissues (P<0.01). These results indicated that activated C-erbB-2, N-ras and altered p53 genes may have a role in human HCC pathogenesis through promiting the development of HCC from hepatic cirrhosis and the progression of HCC.展开更多
基金the Zhejiang Medical and Health Science Foundation (No. 2005A09)
文摘Objective: To understand the relationship between C-erbB-2 and multidrug resistance (MDR) as well as its clini- cal significance. Methods: P-gp level was detected by flow cytometry and simultaneously to examine the C-erbB-2 expression level by immunohistochemistry assay in the operating samples. Their relationship was analyzed from 59 cases with gastric carcinoma. Results: The P-gp positive expression was 38/59 (64.4%) cases with gastric carcinoma. The C-erbB-2 positive expression was 21/59 (35.6%) cases with gastric carcinoma. From the analysis of the P-gp and C-erbB-2 relationship, which was involving, range in the gastric carcinoma, that involving two or three sites were more than the site one, in the cases with C-erbB-2 negative. Compared this two groups, there was a significant difference (P = 0.026). When the C-erbB-2 was positive, the P-gp expression had a significant difference (P = 0.04) in comparing the III–IV stage (lymph node metastasis) with I–II stage (without lymph node metastasis). The tumor’s size, differentiation degree, ages and sex were not related to the C-erbB- 2 and P-gp expression. Conclusion: High level of P-gp expression was related to the C-erbB-2 positive expression in clinical III–IV stage patient with gastric carcinoma (lymph node metastasis). It suggested that the double positive patient might be a poor prognosis. However, when the C-erbB-2 was negative expression, the clinical staging (with lymph node metastasis) was not related to the P-gp expression in gastric carcinoma patients.
文摘Objective: To evaluate factors for prognosis of cervical carcinoma. Methods: Expressions of mn23- HI, erbB3 and erbB4 were examined by immunohistochemical staining. The apoptosis was detected in situ by the TdT mediated duip-biotin nick end-labeling (TUNEL) technique. Mitotic cell were counted by HE dyeing. Results: FIGO stage and lymph node metastasis were the most important factors for evaluating prognosis in adenocarcinoma or squamous cell carcinoma. AI/MI was positively correlated with 5-year survival of cervical carcinoma. Positive expression of nm23-H1 combed with negative expression of erbB4 [nm23-H1(+)/erbB4(?)] predicted good prognosis for adenocarcinoma. In multivariable Cox regression analysis, only FIGO stage and AI/MI were into equation. Conclusion: FIGO stage and AI/MI were independent evaluating parameter for adenocarcinoma or squamous cell carcinoma.
文摘Objective: Aberrant expression of c-erbB-2, p53, p16 has been found in oral squamous cell carcinoma. We therefore examined expression of these proteins in squamous cell carcinoma of the anterior tongue and compared their relationship with clinical stages and prognosis. Methods: Seventy-six patients with squamous cell carcinoma of the anterior tongue never treated before were obtained from Cancer Hospital, CAMS. Archive tissues of carcinoma and paracarcinoma were examined for c-erbB-2, p53 and p16 expression by immunohistochemistry. Results: The rates of immunopositive staining of c-erbB-2, p53 and p16 were 64.5%, 61.8% and 23.7% respectively; the positive rates in paracarcinoma mucosa were 19.7%, 22.6% and 55.3% respectively. Overexpression of c-erbB-2 was significantly correlated with short overall survival, metastasis and staging. Overexpression of paracarcinoma p53 was significantly correlated with local recurrence. Conclusion. c-erbB-2 may be used as a prognosis marker for the patients with squamous cell carcinoma of the anterior tongue and p53 as a recurrence marker.
文摘To assess the relationship between C-erbB-2, p53, N-ras status at a premalignant stage and in HCC, the authors studied the imunohistological expression of these genes in HCC, liver cirrhosis and in the adjacent normal resected liver tissue, using monoclonal antibody to mutated p53 and activated C-erbB-2, N-ras. C-erbB-2 was expressed in 97.1% (35/36) of HCC and 100% (18/18) of hepatic cirrhosis, low level C-erbB-2 expression was observed in 2/14 (14.3%) of normal liver specimens; The positive incidence of overexpression of mutant p53 protein in HCC and hepatic cirrhosis were 55.6% (20/36) and 66.7% (10/18) respectively; 29 (76.5%) specimens of HCC and 16 (88.9%) of hepatic cirrhosis were positive for N-ras protein. The overexpression of the three oncogene proteins were significantly higher than that of normal liver tissues (P<0.01). These results indicated that activated C-erbB-2, N-ras and altered p53 genes may have a role in human HCC pathogenesis through promiting the development of HCC from hepatic cirrhosis and the progression of HCC.